版本:
中国

BRIEF-Protagonist Therapeutics signs deal with J&J to develop bowel drug

May 30 Protagonist Therapeutics Inc

* Protagonist therapeutics enters into worldwide agreement with janssen to co-develop and commercialize ptg-200 for inflammatory bowel disease

* Protagonist therapeutics -to receive a $50 million upfront payment and potentially up to an additional $940 million in development and sales milestones

* Protagonist therapeutics inc says under terms of agreement, double-digit tiered royalties on net sales

* Protagonist therapeutics inc says protagonist and janssen to co-fund development through phase 2

* Protagonist therapeutics inc says co retains option to co-detail u.s. Prescribers Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐